patients and to assess whether intranasal hydroxoco-From the Framingham study, we do know that a wellbalamin application could be an alternative for intradefined ambulatory elderly population showed cobalamin muscular injection. Methods: Six patients with plasma deficiency in nearly 12% of the cohort. 2 It is thought cobalamin concentrations of õ200 ng/L were rethat atrophic gastritis plays a role in the pathogenesis of cruited. A dose of 1500 mg hydroxocobalamin was applied intranasally at days 0, 14, and 21. Plasma cobalathis cobalamin deficiency. After resection of stomach or min concentrations were determined 1 hour after terminal ileum, cobalamin deficiency often ensues, neceshydroxocobalamin application and on days 0, 7, 21, sitating suppletion by intramuscular injections of hy-28, and 35. Results: All patients showed substantial droxocobalamin. Major drawbacks of intramuscular inincrease of cobalamin concentrations 1 hour after intrajections are the general need for medical personnel on a nasal application. In these 6 patients, there was an wordwide scale and the fact that they are sometimes eightfold increase of mean baseline cobalamin concenpainful. A more convenient and less costly alternative trations. All patients showed a sustained increase of treatment would be advantageous to health care and baseline cobalamin concentrations 1 week after prior could improve the compliance of the patient. Recently, intranasal application of hydroxocobalamin. No side efa formulation for nasal administration of hydroxocobalfects were noted. Conclusions: Intranasal application amin has been developed. It provides a fast nasal absorpof hydroxocobalamin in cobalamin-deficient patients retion of hydroxocobalamin with a maximum plasma cosults in fast nasal absorption and leads to sustained increase of baseline cobalamin concentrations.
balamin level reached within 30-60 minutes. 3 This study was designed to investigate the feasibility of vitamin B 12 suppletion by using intranasal application of V hydroxocobalamin in cobalamin-deficient patients and to itamin B 12 or cobalamin mainly exists as hydroxocobalamin, methylcobalamin, and adenosyl cobalaassess whether intranasal hydroxocobalamin application min. These forms of vitamin B 12 are almost entirely found could be an alternative for the monthly parenteral adminin animal tissues. Meat Results 1500 mg intranasal hydroxocobalamin on days 0, 14, and 21. All patients showed a sustained increase of baseline Plasma Cobalamin Concentrations After plasma cobalamin concentration measured 1 week after Intranasal Hydroxocobalamin Application intranasal application of 1500 mg hydroxocobalamin. The Figure 1 shows increases of baseline cobalamin mean increase at day 7 was 84 ng/L, at day 21, 88 ng/ concentration before and 1 hour after nasal application L, at day 28, 59 ng/L. Figure 2 shows mean plasma of hydroxocabalamin at days 0, 14, and 21. In all pacobalamin concentrations with SD in 6 patients at days tients, there was a large increase in cobalamin concentra-0, 7, 14, 21, and 28. The nasal administration of hytions 1 hour after intranasal hydroxocobalamin applicadroxocobalamin was well tolerated, and no signs of irritation. The mean baseline cobalamin concentration before tion or nasal sensitivity were noted. hydroxocobalamin application on days 0, 14, and 21 was
Discussion
To our knowledge, this is the first report to document nasal hydroxocobalamin absorption in vitamin B 12deficient patients. Despite the increase in the use of nasal formulation for systemic drug delivery, much still has to be learned about the exact mechanism of nasal drug absorption. The absorption of water-soluble compounds is dependent on several factors, including contact time with the nasal mucosa and the molecular size of the compound. An inverse relationship has been established between the molecular weight of a drug and the proportion of the intranasal dose absorbed. 4 A log-plot of nasal absorption vs. molecular weight shows good bioavailabil- ing molecular weights. 5 This study provides evidence / 5e1f$$0002 07-16-97 18:46:12 gasa WBS-Gastro for administering vitamin B 12 , in particular inhalation, insufflation, or instillation of cyanocobalamin. [7] [8] [9] The formulations used consisted of low concentrations of cyanocobalamin in isotonic saline solution or lactose powder. Although these applications were reported to be effective and safe, none of these proposals found a follow-up in clinical practice. Apparently the results were not convincing, and the proposed formulations were not very practical. Recently, a nasal gel containing cyanocobalamin has become available commercially. In a letter to the editor, this gel in a dose of 400-500 mg cyanocobalamin was claimed to be effective. 10 We are not aware of any clinical studies that show the efficacy of this product in treating vitamin B 12 -deficient patients. Hydroxocobalamin binds more extensively to plasma proteins and has a longer half time in the body than cyanocobalamin. 11 As a result, hydroxocobalamin is better retained in the body and, therefore, requires less frequent dosing. Moreover, cyanocobalamin is contraindicated in patients with tropical amblyopia and simultaneous tobacco usage and in patients with pernicious anemia with optic neuropathy; hence, hydroxocobalamin is the drug of choice in restoring vitamin B 12 deficiencies. 12, 13 This study shows reproducible nasal hydroxocobalamin absorption and sustained increase of hydroxocobalamin levels in B 12 -deficient patients. The intrasubject and hydroxocobalamin measured 1 hour after nasal application can be explained by differences in nasal mucocilary clearance and variations in spraying technique. that hydroxocobalamin, with a molecular weight of 1346
The sustained increase in baseline cobalamin concendaltons, is well absorbed nasally. Also other hydrophilic tration 1 week after nasal application of hydroxocobalcompounds of comparable size, such as oxytocin (mol amin indicates that hydroxocobalamin has not been elimwt, 1007 daltons), desmopressin (mol wt, 1069 daltons), inated from the body. Our preliminary data suggest that buserelin (mol wt, 1238 daltons), and nafarelin (mol wt, a weekly intranasal application of 1500 mg hydroxocobal-1321 daltons), are absorbed nasally. These drugs have amin would be sufficient to restore cobalamin deficiencies already been on the market for many years in nasal dosage completely. Prolonged studies during several months are forms. The nasal absorption of such relatively large hyneeded to confirm this conclusion. drophylic drugs is thought to be diffusion through aque-In conclusion, the application of intranasal hydroxocoous channels (tight junctions) in the epithelial membalamin in cobalamin-deficient patients results in a fast brane. and adequate absorption through the nasal mucosa and In this preliminary study, intranasal application of one leads to a sustained increase of baseline cobalamin condose of hydroxocobalamin in cobalamin-deficient pacentration. Further studies are needed to investigate the tients leads to an eightfold increase of mean baseline possibility of long-term intranasal application of hycobalamin concentration 1 hour after application, indidroxocobalamin as maintenance therapy in patients who cating rapid absorption of significant amounts of hyneed vitamin B 12 parenterally. droxocobalamin in cobalamin-deficient patients. A single tients.
disease. 5th ed. Philadelphia: Saunders, 1993:999-1000.
Cyanocobalamin was the first vitamin B 12 isolated and 2. Lindenbaum J, Rosenberg IH, Wilson PWF, Stabler SP, Allen RH.
introduced for parenteral use in 1948. 6 In the early Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994;60:2-11.
1950s, a few investigators proposed an alternative route / 5e1f$$0002 07-16-97 18:46:12 gasa WBS-Gastro
